Non-[18F]FDG PET in clinical oncology-Reference-Cited by-同舟云学术

Non-[18F]FDG PET in clinical oncology

Published:2007-09 Issue:9 Volume:8 Page:822-830
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Groves Ashley M,Win Thida,Haim Simona Ben,Ell Peter J

Publisher

Elsevier BV

Subject

Oncology

Reference76 articles.

1. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution;Hamacher;J Nucl Med,1986

2. 18F-fluorodeoxyglucose PET/CT in cancer imaging;Kayani;Clin Med,2006

3. Clinical applications of PET in oncology;Rohren;Radiology,2004

4. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development;Kelloff;Clin Cancer Res,2005

5. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast;Langsteger;Semin Nucl Med,2006

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in nanomedicine for metabolism-targeted cancer therapy;Chemical Communications;2024

2. Modulating Glycolysis to Improve Cancer Therapy;International Journal of Molecular Sciences;2023-01-30

3. Role of PET/Computed Tomography in Elderly Thyroid Cancer;PET Clinics;2023-01

4. Addressing the gaps in homeostatic mechanisms of copper and copper dithiocarbamate complexes in cancer therapy: a shift from classical platinum-drug mechanisms;Dalton Transactions;2023

5. Automatic Production of [18F]F-DOPA Using the Raytest SynChrom R&D Module;Pharmaceuticals;2022-12-22